Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term rollover study of VX-661 plus ivacaftor in cystic fibrosis with F508del CFTR mutation
NL-OMON50237Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tezacaftor and ivacaftor in cystic fibrosis (CF) (2 cohorts), sponsored by Vertex Pharmaceuticals. Primary endpoint: Long-term safety and tolerability. Started Dec 2015; status: active, not recruiting.
02
Drugs
tezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON50237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50237.